Trial Profile
Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Apr 2024 Status changed from recruiting to completed.
- 27 Jun 2018 New trial record